Evidence map›Paper›PMID 42751279›Full record

ArticleOpen forum infectious diseases2026

The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System.

Bradley K Ackerson, Brandon Chia, Negar Aliabadi, Gabriella Goodwin, Jeff Slezak, Vennis Hong, Qing Liu, Sally Shaw, Sabrina Welsh, Julie A Stern and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Bradley K AckersonDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-0816-7345
Brandon ChiaDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Negar AliabadiUS Medical Affairs, Pfizer, New York, New York, USA.ORCID https://orcid.org/0000-0002-9264-5089
Gabriella GoodwinDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Jeff SlezakDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-6108-9198
Vennis HongDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Qing LiuData Sciences, Pfizer, New York, New York, USA.
Sally ShawDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-6553-1772
Sabrina WelshResearch and Development, Pfizer, New York, New York, USA.ORCID https://orcid.org/0009-0000-7690-0062
Julie A SternDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Banshri KapadiaDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Brigitte C SpenceDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-2386-9967
Joseph A LewnardDivisions of Epidemiology, and Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, USA.
Gregg DavisDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Evan J ZasowskiResearch and Development, Pfizer, New York, New York, USA.ORCID https://orcid.org/0000-0002-2595-1860
Michael AragonesDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Ashley MillerUS Medical Affairs, Pfizer, New York, New York, USA.ORCID https://orcid.org/0000-0002-9754-9731
Michael DutroUS Medical Affairs, Pfizer, New York, New York, USA.ORCID https://orcid.org/0009-0005-7634-2183
Erica ChilsonUS Medical Affairs, Pfizer, New York, New York, USA.
Elisa GonzalezResearch and Development, Pfizer, New York, New York, USA.
Robin HublerResearch and Development, Pfizer, New York, New York, USA.
Luis JodarIndependent Advisor, Pfizer, New York, New York, USA.
Bradford D GessnerEpiVac Consulting, Pfizer, New York, New York, USA.
Elizabeth BegierResearch and Development, Pfizer, New York, New York, USA.ORCID https://orcid.org/0000-0002-1287-5416
Sara Y TartofDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infrequent standard-of-care (SOC) testing for respiratory syncytial virus (RSV) in adults with acute respiratory illness (ARI) contributes to underestimated disease burden. Methods: We compared RSV prevalence and RSV vaccine effectiveness (VE) among 14 044 adults ≥60 years with ARI emergency department (ED)/hospital admissions receiving SOC RSV testing vs those with SOC or salvaged respiratory specimen RSV testing. Results: RSV was identified in 139 (0.99%) specimens by SOC testing alone vs 483 (3.44%) via SOC combined with salvage testing. Conclusions: Precision of VE against RSV-related ARI ED/hospital admissions improved substantially with inclusion of salvage testing compared to SOC testing alone (92% [67%-98%] vs 90% [29%-99%]).

Indexed as

prevalencerespiratory syncytial virusundertestingvaccine effectiveness

Identifiers

PMID42751279
PMCPMC13579481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.